585
Views
5
CrossRef citations to date
0
Altmetric
Research Articles

Olmesartan/Amlodipine Combination Versus Olmesartan or Amlodipine Monotherapies on Blood Pressure and Insulin Resistance in a Sample of Hypertensive Patients

, , , , , & show all
Pages 301-307 | Received 18 Jun 2012, Accepted 11 Jul 2012, Published online: 06 Sep 2012

REFERENCES

  • Wolf-Maier K, Cooper RS, Kramer H, Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43(1):10–17.
  • Derosa G, Maffioli P. Drug safety evaluation of amlodipine. Expert Opin Drug Saf 2011; 10(5):795–804.
  • Derosa G, Maffioli P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Rev Cardiovasc Ther 2010; 8(6):835–843.
  • Fogari R, Zoppi A, Mugellini A, Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. Expert Opin Pharmacother 2012; 13(5):629–636.
  • Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30(4):587–604.
  • Kretuz R. Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc Health Risk Manag 2011; 7:183–192.
  • Lichtenstein AH, Appel LJ, Brands M, Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006; 26:2186–2191.
  • European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16:716–730.
  • Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8:260–266.
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–419.
  • Klose S, Enzymatische BK. Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978; 15:121–130.
  • Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bermeyer HU, ed. Methods of Enzymatic Analysis, 2nd (English) ed. New York, NY: Academic Press, Inc., 1974:18–31.
  • Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34:1345–1353.
  • Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.
  • De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:214–223.
  • Ferrannini E, Buzzigoli G, Bonadonna R, Insulin resistance in essential hypertension. N Engl J Med 1987; 317(6):350–357.
  • Winer BJ. Statistical Principles in Experimental Design, 2nd ed. New York, NY: McGraw-Hill, 1971.
  • Sugihara M, Miura S, Takamiya Y, Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009; 32(7):625–630.
  • Fukao K, Shimada K, Hiki M, Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on glucose tolerance and endothelial function-a crossover trial (AGENT). Cardiovasc Diabetol 2011; 10:79.
  • Dohi T, Narui K, Kasai T, Effects of olmesartan on blood pressure and insulin resistance in hypertensive patients with sleep-disordered breathing. Heart Vessels 2011; 26(6):603–608.
  • Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, Soriano-Perera P, Pedrianes-Martin P, Comi-Diaz C. Olmesartan/amlodipine vs. olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 2011; 25(6):346–353.
  • Derosa G, Maffioli P, Salvadeo SA, Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res 2010; 33(8):790–795.
  • Fogari R, Malamani G, Corradi L, Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. Adv Ther 2010; 27(1):48–55.
  • Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8):713–719.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.